March 14, 2022 5:08pm
It didn’t, although most risks are already priced into this market; it’s close as algorithms hopefully will create a trend and be a friend – I’d be buying into weakness
Pre-open indications: 3 Hits and 6 Miss
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
The multiple metrics and Bottom Line say it all succinctly … just the facts
Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read the facts supported by real numbers?
If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.
The Dow closed UP +1.05 points (+0.00%); the S&P closed DOWN -31.22 points (-0.74%) while the Nasdaq closed DOWN -262.59 points (-2.04%)
Henry’omics:
Indexes were mixed as the S&P and Nasdaq fell over war’s visibility and anticipating a rate hike by the Fed this week.
If historical precedent offers any guidance, the currently high valuations of the S&P 500, which remain elevated even after recent declines, mean that a prolonged bear market is likely in the near future. Furthermore, the Russian invasion of Ukraine may guarantee it. A comparison between the Iraqi invasion of Kuwait 32 years ago and the current conflict in Eastern Europe may help illustrate why.
Iraq invaded Kuwait on Aug. 2, 1990 and defeated it within days. Although Kuwait’s population was much smaller than Ukraine’s is now, its invasion by Saddam Hussein was an affront to NATO and OPEC countries. Kuwait didn’t rank among the top 10 global energy producers, yet the S&P 500 dropped 16% and the Nasdaq Composite index fell 25%, as oil rose from $28 to $46 a barrel by mid-October that year. <Barron’s>
52-week low:
· Precigen (PGEN) at $1.89
· bluebird bio (BLUE) at $4.11
· Caribou Therapeutics (CRBU) at $8.46
· uniQure NV (QURE) at $14.81
· Sage Therapeutics (SAGE) at $30.67
· Fate Therapeutics (FATE) at 29.79
· Ultragenyx (RARE) at 461.44
· Beam Therapeutics (BEAM) at $55.74
· XBI at 80.85
This a.m.’s post, RegMed Investors’ (RMi) pre-open: “the phoenix rises from the shares as do share pricings after being burned to a crisp. Time to say, HELLO clearer skies (i.e., upside) to a few cell and gene therapy sector equities” … https://www.regmedinvestors.com/articles/12339
RegMed/Stem/Cell and Gene therapy’s 36 covered equities’ Advance/Decline (A/D) lines: what happened …
- Monday opened negative at 15 up/22 downs, 1 flat, stayed negative at the mid-day at 4/31 and 2 flats, ending with a negative close of 4/30 and 1 flat;
Pre-open Indications: 3 Hits <Biostage (BSTG -$0.00), CRISPR Therapeutics (CRSP -$3.36), Vericel (VCEL -$1.40)> 6 Miss < Sage Therapeutics (SAGE -$0.36), Beam Therapeutics (BEAM -$7.18), Caribou Therapeutics (CRBU -$0.77), Cellectis SA (CLLS -$0.31), Editas Medicine (EDIT -$0.98), Intellia Therapeutics (NTLA -$2.49),
RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 … (SLDB) added
The Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works with Monday’s flat with 28 shares traded after Friday’s 1,602 shares trading up +$0.39, Thursday -$0.63 with 488 shares traded, Wednesday -$0.26 with 1,225 shares traded, Tuesday flat with 1,130 shares traded and last Monday’s close +$0.29 with 399 shares traded,
- WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
- A “zombie” company funded by non-U.S. Beijing, China entities
- By use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering
- BSTG is NOT going ANYWHERE without a cash inflow.
Key Metrics:
- Monday - Sector volume was LOW with 1 of the 4-upside having higher than the 3-month average volume with LOW volume of 9 of 30-downside having higher than the 3-month average volume;
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Monday, the IBB was down -0.87% and the XBI was down -4.18%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Monday was up +1.02 points or +3.32% at 31.77
Jumping with share pricing momentum (4 of 4):
- Voyager Therapeutics (VYGR +$0.61),
- Global Blood Therapeutics (GBT +$0.58),
- Ionis Pharmaceuticals (IONS +$0.49),
- Mesoblast (MESO +$0.16),
Hammered in today’s market (10 of 30):
- Beam Therapeutics (BEAM -$7.18),
- Fate Therapeutics (FATE -$3.88),
- CRISPR Therapeutics (CRSP -$3.36),
- Ultragenyx (RARE -$3.21),
- Alnylam Pharmaceuticals (ALNY -$3.16),
- Intellia therapeutics (NTLA -$2.49),
- BioLife Solutions (BLFS -$2.12),
- Regenxbio (RGNX -$2.05),
- Vericel (VCEL -$1.40),
- Editas Medicine (EDIT -$0.98),
Closing Flat:
- Biostage (BSTG)
March, Q1/2022:
- Monday closed negative with 5 incliners, 30 decliners and 1 flat
The BOTTOM LINE: The reality is that investors remain very fearful on adding extra risk in this time of conflict uncertainty.
Gains have been erased and I believe opening the door for a rebound – but, when as I am usually early in “calling this ball”.
Does “our universe’s” reaction revolve around the Fed expecting the federal funds rate to rise with a target range of 0.25%-0.5% Wednesday to fight inflation with interest-rate hikes.
It’s not the whole picture – the sector needs an action item to offset the divergences to the bottoms.
But how fast the Fed will hike rates is still in question, especially amid growing concerns about a slowdown for the U.S. economy.
As stated, uncertainty definitely surrounded the cell and gene therapy sector …
The sector was mostly lower, stripped equities of any upside (the downfall range was -0.32% to -14.89% while the upside placed its forward motion +1.52% to +10.91%.
The cell and gene therapy sector’s volume remained LOW.
Remember the adage, “It takes two to make a market"; that’s sellers and buyers.
I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.
Q4 and end-of-year earnings are still “gamy” than even I thought.
Earnings’ reporting coming:
· Athersys (ATHX), Tuesday, 3/15
· Cellectis SA (CLLS) Thursday, 3/22,
· Brainstorm Cell Therapeutics (BCLI), Monday, 3/28
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it defines purpose that takes courage, resolve and patience to stay the course of asking the questions without response!
